{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-012244","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.091607+00:00","generated_at":"2026-05-26T23:14:51.171167+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Oramed spins off oral insulin into OraTech JV with HTIT; $75M total investment, Nasdaq IPO planned","bullets":["HTIT to invest $60M, Oramed $15M into OraTech; Oramed shareholders to receive direct stake in new Nasdaq-listed company.","OraTech to launch Phase 3 trial of oral insulin (ORMD-0801) in US this quarter with revised protocol.","HTIT provides supply agreement for oral insulin capsules; OraTech gets global marketing rights to Oramed's POD technology.","OraTech also receives license for oral semaglutide (HT01B) from HTIT for markets outside greater China.","Initial closing deadline extended to April 30, 2025; second closing by May 31, 2025 if Nasdaq listing delayed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-012244","json":"https://secwatch.observer/filing/0001213900-25-012244.json","markdown":"https://secwatch.observer/filing/0001213900-25-012244.md","text":"https://secwatch.observer/filing/0001213900-25-012244.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012244/0001213900-25-012244-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025012244/ea0229914-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:14:51.171167+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}